Research Article
Predictors of Visual Response to Intravitreal Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration
Table 2
Predictors of visual acuity score change and central retinal thickness change from baseline at 6 months.
| Baseline characteristics | VA score change | CRT change (m) | Letters | ≥15 letters gain | | Median | | | Mean ± SD | | (%) | |
| Age (years) | | | | | | | | | 50–59 | 26 | | 0.227 | 12 (46.2) | 0.393 | 22 | −47.0 | 0.504 | 60–69 | 43 | | 13 (30.2) | 42 | −130.0 | 70–79 | 62 | | 17 (27.4) | 58 | −77.5 | ≥80 | 13 | | 4 (30.8) | 10 | −128.5 | Gender | | | | | | | | | Male | 95 | | 0.928 | 31 (32.6) | 0.805 | 86 | −64.0 | 0.052 | Female | 49 | | 15 (30.6) | 46 | −122.0 | Smoking | | | | | | | | | No | 77 | | 0.996 | 26 (33.8) | 0.659 | 72 | −106.5 | 0.047 | Yes | 66 | | 20 (30.3) | 59 | −56.0 | Lesion type | | | | | | | | | Occult only | 57 | | 0.832* | 13 (22.8) | 0.104 | 55 | −67.0 | 0.352 | Minimally classic | 21 | | 10 (47.6) | 20 | −117.0 | Predominantly classic | 49 | | 15 (30.6) | 47 | −82.0 | Treatment regimen | | | 0.035 | | 0.626 | | | 0.492 | A | 74 | | | 25 (33.8) | | 65 | −103.0 | | B | 70 | | | 21 (30.0) | | 67 | −56.0 | |
|
|
CRT: central retinal thickness; SD: standard deviation; VA: visual acuity.
*Nonparametric testing.
|